ArticleBMC infectious diseases2025
Clinical characteristics of Mycoplasma pneumoniae compared to Streptococcus pneumoniae in hospitalized adults with community-acquired pneumonia- a prospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Complete Blood Count-Derived Inflammatory Markers in Pediatric Lower Respiratory Tract Infection: A Narrative Review.Pathogens (Basel, Switzerland) · 2026Review
- Correction to: Clinical characteristics of Mycoplasma pneumoniae compared to Streptococcus pneumoniae in hospitalized adults with community-acquired pneumonia- a prospective study.BMC infectious diseases · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStreptococcus pneumoniae is the primary cause of hospitalized community-acquired pneumonia (CAP). Mycoplasma pneumoniae, though typically causing mild respiratory disease, can lead to pneumonia requiring hospitalization in adults. This study compared patients hospitalized with CAP caused by M. pneumoniae or S. pneumoniae aiming at increasing the understanding of when to sample for and empirically treat M. pneumoniae.
methodsFrom 2016 to 2018, 518 adults hospitalized with CAP were prospectively and consecutively enrolled. Medical history, symptoms, radiographic, and laboratory data were recorded. Naso- and oropharyngeal swabs were collected for PCR detection of M. pneumoniae and other respiratory pathogens, while urine samples were analysed with two pneumococcal urinary antigens.
resultsA total of 32 patients with M. pneumoniae and 126 patients with S. pneumoniae were identified. Patients with M. pneumoniae were significantly younger than those with pneumococcal CAP with a median age 39 versus 70 years. Mycoplasma pneumoniae accounted for only 6% of CAP cases across all ages, but for 33% of cases in patients < 50 years. Mycoplasma pneumoniae patients had a longer duration of symptoms and were more often prescribed antibiotics prior to hospital admission. Neither symptoms nor chest imaging alone could distinguish between M. pneumoniae and S. pneumoniae. Although inflammatory markers such as CRP and leukocyte counts were significantly lower in M. pneumoniae CAP, the median CRP value was still elevated at 178 mg/L. Viral co-detection occurred in 14% of M. pneumoniae patients, compared to 42% of those with S. pneumoniae.
conclusionSymptoms and radiological findings could not distinguish between M. pneumoniae and S. pneumoniae. However, in hospitalized patients, particularly in younger individuals or those with antibiotic failure, liberal testing and treatment for M. pneumoniae is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.